SCR-LIP-000328 · Claim · machine-readable JSON →
This narrative review proposes, on a mechanistic/theoretical basis, that gestrinone (a 19-nortestosterone progestin acting via PRβ to increase 17β-HSD2 and inhibit 17β-HSD1 and aromatase) could reduce local estradiol accumulation and ERα overactivation in lipedema adipose tissue, but presents no clinical intervention data or outcomes in lipedema patients.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- very low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 1 question(s)
- Dates
- 2026-05-31 → 2026-05-31
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31
Evidence over time
Evidence (1)
- Hormonal Links between Lipedema and Gynecological Disorders: Therapeutic Roles of Gestrinone and Drospirenone — Viana & Câmara (2025) ✓ verified — contextual · review · 2025 · reading confidence: high
“Não há intervenção (revisão narrativa).”
Narrative review that only hypothesizes a therapeutic role for gestrinone based on shared hormonal mechanisms with gynecological disorders; no intervention, no clinical efficacy data in lipedema patients, so it provides theoretical context
Context (PECO)
Answers these questions
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-05-31 — created · auto-ingested for SQ-LIP-000016